Sab Biotherapeutics Stock Short Ratio
| SABS Stock | USD 3.03 0.10 3.19% |
SAB Biotherapeutics fundamentals help investors to digest information that contributes to SAB Biotherapeutics' financial success or failures. It also enables traders to predict the movement of SAB Stock. The fundamental analysis module provides a way to measure SAB Biotherapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to SAB Biotherapeutics stock.
SAB | Short Ratio |
SAB Biotherapeutics Company Short Ratio Analysis
SAB Biotherapeutics' Short Ratio is typically used by traders and speculators to identify trends in current market sentiment for a particular equity instrument. In its simple terms this ratio shows how many days it will take all current short sellers to cover their positions if the price of a stock begins to rise.
Current SAB Biotherapeutics Short Ratio | 0.54 X |
Most of SAB Biotherapeutics' fundamental indicators, such as Short Ratio, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, SAB Biotherapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
SAB Short Ratio Driver Correlations
Understanding the fundamental principles of building solid financial models for SAB Biotherapeutics is extremely important. It helps to project a fair market value of SAB Stock properly, considering its historical fundamentals such as Short Ratio. Since SAB Biotherapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of SAB Biotherapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of SAB Biotherapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
The higher the Short Ratio, the longer it would take to buy back the borrowed shares. In theory, the more short positions are currently outstanding, the faster it will be to cover shorted positions.
| Competition |
SAB Price To Sales Ratio
Price To Sales Ratio |
|
Based on the latest financial disclosure, SAB Biotherapeutics has a Short Ratio of 0.54 times. This is 86.15% lower than that of the Biotechnology sector and 92.71% lower than that of the Health Care industry. The short ratio for all United States stocks is 86.5% higher than that of the company.
SAB Short Ratio Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses SAB Biotherapeutics' direct or indirect competition against its Short Ratio to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of SAB Biotherapeutics could also be used in its relative valuation, which is a method of valuing SAB Biotherapeutics by comparing valuation metrics of similar companies.SAB Biotherapeutics is currently under evaluation in short ratio category among its peers.
SAB Biotherapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, SAB Biotherapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to SAB Biotherapeutics' managers, analysts, and investors.Environmental | Governance | Social |
SAB Biotherapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in SAB Biotherapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of SAB Biotherapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing SAB Biotherapeutics' value.| Shares | Institutional & Family Asset Management, Llc | 2024-06-30 | 19.2 K | Blackrock Inc | 2024-06-30 | 13.8 K | Citadel Advisors Llc | 2024-09-30 | 10.3 K | Advisor Group Holdings, Inc. | 2024-06-30 | 4.5 K | Tower Research Capital Llc | 2024-06-30 | 2.4 K | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 1.4 K | Princeton Global Asset Management Llc | 2024-09-30 | 500 | Gs Investment Inc | 2024-09-30 | 200 | Bank Of America Corp | 2024-06-30 | 165 | Bvf Inc | 2024-09-30 | 917.8 K | Rtw Investments, Llc | 2024-06-30 | 766.9 K |
SAB Fundamentals
| Return On Equity | -1.75 | ||||
| Return On Asset | -0.79 | ||||
| Operating Margin | (34.23) % | ||||
| Current Valuation | 3.01 M | ||||
| Shares Outstanding | 9.23 M | ||||
| Shares Owned By Insiders | 19.15 % | ||||
| Shares Owned By Institutions | 34.24 % | ||||
| Number Of Shares Shorted | 58.76 K | ||||
| Price To Book | 0.78 X | ||||
| Price To Sales | 19.10 X | ||||
| Revenue | 2.24 M | ||||
| Gross Profit | (12.53 M) | ||||
| EBITDA | (38.13 M) | ||||
| Net Income | (42.19 M) | ||||
| Cash And Equivalents | 16.62 M | ||||
| Cash Per Share | 0.39 X | ||||
| Total Debt | 5.91 M | ||||
| Debt To Equity | 0.16 % | ||||
| Current Ratio | 1.72 X | ||||
| Book Value Per Share | 4.00 X | ||||
| Cash Flow From Operations | (25.12 M) | ||||
| Short Ratio | 0.54 X | ||||
| Earnings Per Share | (6.30) X | ||||
| Target Price | 12.4 | ||||
| Number Of Employees | 57 | ||||
| Beta | 0.64 | ||||
| Market Capitalization | 28.89 M | ||||
| Total Asset | 83.94 M | ||||
| Retained Earnings | (90.06 M) | ||||
| Working Capital | 48.09 M | ||||
| Net Asset | 83.94 M |
About SAB Biotherapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze SAB Biotherapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of SAB Biotherapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of SAB Biotherapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for SAB Stock Analysis
When running SAB Biotherapeutics' price analysis, check to measure SAB Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy SAB Biotherapeutics is operating at the current time. Most of SAB Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of SAB Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move SAB Biotherapeutics' price. Additionally, you may evaluate how the addition of SAB Biotherapeutics to your portfolios can decrease your overall portfolio volatility.